Ottobock Enters Exclusive Distribution of the BiOM Prosthetic Ankle in Select European Markets - Gilde Healthcare

Ottobock Enters Exclusive Distribution of the BiOM Prosthetic Ankle in Select European Markets

December 9, 2015

BEDFORD, Mass.–(BUSINESS WIRE)–We are pleased to announce that Otto Bock HealthCare GmbH and BionX Medical Technologies, Inc. have agreed to collaborate closely. Effective immediately, Ottobock is the exclusive distributor of the BiOM prosthetic ankle in Germany, Austria, Switzerland and the Scandinavian markets.

The BiOM prosthetic ankle is the world’s first and only commercially available device with powered propulsion in the mechatronic ankle prosthetic class. The motor-driven ankle system expands Ottobock’s product portfolio of highly modern prosthetic feet and offers additional degrees of ankle movement to amputees.

“We are very pleased about our partnership with this innovative company,” says Dr. Helmut Pfuhl, Head of the Prosthetics Business Unit at Ottobock. He emphasizes that both companies share similar values and have entered into a partnership built upon strong collaboration. “BionX and Ottobock are a good fit. Our shared goal is to keep offering new possibilities to amputees through innovative products and personalized fitting options, helping them be more mobile in their everyday life, work and leisure time”, says Dr. Helmut Pfuhl.

Taras Rebet, President Western Europe Region at Ottobock, is positive about this partnership as well: “I’m very confident and pleased that our local Sales and Marketing organizations in the selected countries are well prepared and eager to contribute successfully to this partnership. Ottobock has been well established in those countries with its own sales organizations for many decades now and we act with the suitable strength of a local player supported by the international structure of the Ottobock Group”.

“We are very excited about our partnership with Ottobock, a pioneer and market leader in orthotics and prosthetics,” said Charles Carignan, MD, President & CEO of BionX Medical Technologies, Inc. “This partnership will further expand our ability to offer normalized limb function and improved quality of life to enable more people around the world to realize their full potential.”

About Ottobock:

For people with limited mobility, Ottobock develops medical technology products and fitting concepts in the fields of Prosthetics, Orthotics, Mobility Solutions (wheelchairs, rehabilitation aids) and MedicalCare. Ottobock has been a family-managed company since it was founded in 1919. Today it has subsidiaries in 55 countries with more than 6,300 employees. As the global leader in exo-prosthetics, products particularly in this area are constantly setting standards in the prosthetic care of people with disabilities. HealthCare Deutschland GmbH is responsible for distribution in Germany, Austria and Switzerland. Sales in Scandinavia are regulated by Scandinavia AB.

 

First Enrolment in the ProVIDE Clinical Study for BPH Treatment

ProVerum Limited, an Irish medical device company developing a minimally invasive solution to treat benign prostatic hyperplasia (BPH) in the doctor’s office, today announced the commencement of the ProVIDE pivotal clinical trial to evaluate the...
June 10, 2022

Gilde Healthcare company Big Health receives NICE digital therapeutics guidance confirming clinical and cost effectiveness

Big Health has become the first digital therapeutics company to receive guidance from the National Institute for Health and Care Excellence (NICE), which has recommended Sleepio as a cost-saving option for treating insomnia in a move that heralds...
May 20, 2022

Gilde Healthcare portfolio company Synexa Life Sciences acquires Finnish CRO Syrinx Bioanalytics to expand bioanalysis capabilities in clinical drug development

Gilde Healthcare portfolio company Synexa Life Sciences BV, a global leader in specialist biomarker and bioanalysis research services, has today announced that it has acquired Syrinx Bioanalytics, a bioanalytical CRO based in Turku, Finland. The move...
May 19, 2022